Table of Contents PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Symptoms • Causes • Risk factors • Complications • Tests and diagnosis • Key buying criteria PART 06: Pipeline analysis PART 07: Market landscape • Global respiratory syncytial virus drugs market • Five forces analysis PART 08: Market segmentation by category of drug • Approved Drugs • Off-label drugs PART 09: Geographical segmentation • Human respiratory syncytial virus drugs market in US • Human respiratory syncytial virus drugs market in Europe • Human respiratory syncytial virus drugs market in ROW PART 10: Market drivers • Presence of large patient pool fuels market growth • Launch of novel products • Novel diagnostic tools increase patient population PART 11: Impact of drivers PART 12: Market challenges • Continuous change in guidelines from healthcare organizations impacts market growth • Cyclical nature of market hinders growth opportunities • Limited drugs in market leading to low penetration rates PART 13: Impact of drivers and challenges PART 14: Market trends • Emergence of new entrants likely to change market dynamics • Growing strategic collaborations fostering innovation • Active participation from emerging economies toward R&D PART 15: Vendor landscape • Competitive scenario PART 16: Key vendor analysis • AstraZeneca • AbbVie • GSK • Teva Pharmaceutical • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key customer segments of global human respiratory syncytial virus drugs market Exhibit 03: Snapshot of RSV infection Exhibit 04: Key buying criteria for RSV drugs Exhibit 05: Factors affecting the adoption rates of RSV drugs Exhibit 06: Pipeline analysis of key vendors in global human respiratory syncytial virus drugs market Exhibit 07: Percentage share of drug candidates by stage of development Exhibit 08: Pipeline candidates: Global human respiratory syncytial virus drugs market Exhibit 09: Global human respiratory syncytial virus drugs market snapshot Exhibit 10: Analysis of global human respiratory syncytial drugs market Exhibit 11: Global human respiratory syncytial virus drugs market 2015-2020 ($ billions) Exhibit 12: Emerging vendors and their initiatives Exhibit 13: Opportunity analysis of global respiratory syncytial virus drugs market Exhibit 14: Opportunity analysis in developed and emerging markets Exhibit 15: Five forces analysis Exhibit 16: Segmentation of global human respiratory syncytial virus drugs market by type of drug 2015 Exhibit 17: Segmentation of global human respiratory syncytial virus drugs market based on geography 2015 and 2020 Exhibit 18: Global human respiratory syncytial virus drugs market revenue by geography 2015-2020 ($ millions) Exhibit 19: Incidence of RSV infections in US (on average every year) Exhibit 20: Global human respiratory syncytial virus drugs market in US 2015-2020 ($ millions) Exhibit 21: Key drivers and challenges in US Exhibit 22: Human respiratory syncytial virus drugs market in Europe 2015-2020 ($ millions) Exhibit 23: Trends in global human respiratory syncytial drugs market in Europe Exhibit 24: Global human respiratory syncytial virus drugs market in ROW 2015-2020 ($ millions) Exhibit 25: Key drivers and challenges in ROW Exhibit 26: Trends in RSV epidemics Exhibit 27: Potential products Exhibit 28: Impact of drivers Exhibit 29: Change in guidelines of AAPCID and its consequences Exhibit 30: Impact of cyclical nature of RSV epidemics Exhibit 31: Factors affecting penetration rates Exhibit 32: Forcefield analysis of drivers and challenges in global human respiratory syncytial virus drugs market Exhibit 33: Impact of drivers and challenges Exhibit 34: Potential entrants Exhibit 35: Strategic alliances Exhibit 36: Competitive structure analysis of global human respiratory syncytial virus drugs market 2015 Exhibit 37: Market share analysis 2015 Exhibit 38: Market penetration of various RSV drug manufacturers in global human respiratory syncytial virus drugs market (2015) Exhibit 39: Strategic success factors of companies in global human respiratory syncytial virus drugs market Exhibit 40: AstraZeneca: Key highlights Exhibit 41: AstraZeneca: Strength assessment Exhibit 42: AstraZeneca: Strategy assessment Exhibit 43: AstraZeneca: Opportunity assessment Exhibit 44: AstraZeneca: Revenue of Synagis 2013-2015 ($ billions) Exhibit 45: AstraZeneca: Geographic segmentation of Synagis 2015 Exhibit 46: AbbVie: Strength assessment Exhibit 47: AbbVie: Strategy assessment Exhibit 48: AbbVie: Opportunity assessment Exhibit 49: AbbVie: Revenue of Synagis 2013-2015 ($ millions) Exhibit 50: GSK: Profile Exhibit 51: GSK: Strength assessment Exhibit 52: GSK: Strategy assessment Exhibit 53: GSK: Opportunity assessment Exhibit 54: GSK: Revenue of Ventolin 2013-2015 ($ billions) Exhibit 55: GSK: Geographical segmentation of Ventolin 2015 Exhibit 56: Teva Pharmaceutical: Profile Exhibit 57: Teva Pharmaceutical: Strength assessment Exhibit 58: Teva Pharmaceutical strategy assessment Exhibit 59: Teva Pharmaceutical: Opportunity assessment Exhibit 60: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)

Other Prominent Vendors in the market are: Askon Engineers, Bio JetDrier, HOKWANG INDUSTRIES, Taishan Jieda Electrical Industrial, Panasonic, and Palmer Fixture.